Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Galapagos, a Belgium-based biotech firm, has reported positive results from its randomized, double-blind, placebo-controlled, single centre Phase I trial of its first-in-class molecule, GLPG1690, to treat patients with pulmonary disease.
Subscribe to our email newsletter
The company is developing GLPG1690 in collaboration with Janssen Pharmaceutica.
Around 40 healthy volunteers were included in the trial, which evaluated the safety, tolerability, pharmacokinetics and pharmacodynamics of oral single and multiple ascending doses of GLPG1690.
In the trial’s first part, single ascending doses were evaluated, while in the second part, the new compound was administered daily for 14 days.
Galapagos CSO Dr Piet Wigerinck said: "GLPG1690 is the first molecule against this target ever to be evaluated clinically, and we are pleased with the outcome of the Phase I study.
"Galapagos continues to deliver novel therapeutics from its unique target and drug discovery engine."
The company said that GLPG1690 proved to be safe and well-tolerated over a wide dose range in healthy volunteers.
Under a deal signed in 2007, Galapagos provided Janssen Pharmaceutica the option to worldwide, commercial licenses to certain Galapagos internal inflammatory disease programs, which are based on new targets for inflammatory disorders.